Nasdaq IPOs

The AZEK Company, which manufactures composite residential and commercial building products, announced terms for its IPO on Monday. The Chicago, IL-based company plans to raise $625 million by offering 31.3 million shares at a price range of $19 to $21. At the midpoint of the pro

Royalty Pharma, which buys royalty interests in marketed and late-stage biopharmaceuticals, announced terms for its IPO on Monday. The New York, NY-based company plans to raise up to $2.0 billion by offering 70 million shares (14% insider) at a price range of $25 to $28. At the m

Vaxcyte, a preclinical biotech developing pneumococcal vaccines, announced terms for its IPO on Monday. The Foster City, CA-based company plans to raise $210 million by offering 14 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Vaxcyte would

Updated Monday, 6/8. Following the busiest week yet for the 2020 IPO market, another eight IPOs and one SPAC plan to raise $2 billion in the week ahead, led by building products maker AZEK (AZEK) online auto marketplace Vroom (VRM). In the largest deal of the week, AZEK (AZE

Updated Monday, 6/8. Following the busiest week yet for the 2020 IPO market, another eight IPOs and one SPAC plan to raise $2 billion in the week ahead, led by building products maker AZEK (AZEK) online auto marketplace Vroom (VRM). In the largest deal of the week, AZEK (AZE

Following the busiest week yet for the 2020 IPO market, three IPOs plan to raise $431 million in the week ahead, led by online auto marketplace Vroom (VRM). After increasing its range on Friday, Vroom (VRM) plans to raise $356 million at a $2.3 billion market cap. With $1.3 billi

Eight companies entered the public market in the busiest week yet for the IPO market. For the first time since June 2018, all eight IPOs raised more than originally expected, either by pricing above the range or upsizing their offerings. They were joined by two SPACs. In its ret

ArcherDX, which provides genomic testing products for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. ArcherDX is a genomics company that offers a suite of products and services for clinicians, as well as biopharmaceuticals looking

Akouos, a preclinical biotech developing gene therapies for inner ear disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Akouos' pipeline contains lead candidate AK-OTOF, a gene therapy for the treatment of hearing lo

PolyPid, a Phase 3 biotech developing extended-release drugs to prevent surgical site infections, filed on Friday with the SEC to raise up to $58 million in an initial public offering. This is the third time PolyPid has filed to go public. It last filed in February 2018 but withd

Fusion Pharmaceuticals, a Phase 1 biotech developing precision medicines for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Fusion's pipeline contains lead candidate FPI-1434, which is designed to target and de

Agora, which offers a platform for API development, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The key component in Agora's platform is Agora SDK, which allows developers to embed real-time engagement functions such as interactive vide

Burning Rock Biotech, which provides DNA sequencing-based cancer therapy selection tests in China, announced terms for its IPO on Friday. The company plans to raise an additional $25 million in a concurrent private placement to Lake Bleu Capital. The Guangzhou, China-based compan

Vroom, an online used car marketplace, raised the proposed deal size for its upcoming IPO on Friday. The New York, NY-based company now plans to raise $356 million by offering 18.75 million shares at a price range of $18 to $20, up from the original range of $15 to $17. At the mi

Legend Biotech, a clinical stage CAR-T immuno-oncology biotech being spun out of GenScript, raised $424 million by offering 18.4 million ADSs at $23, above the range of $18 to $20. Legend Biotech plans to list on the Nasdaq under the symbol LEGN. Morgan Stanley, J.P. Morgan and J

Dada Nexus, a leading on-demand retail and delivery platform in China, raised $320 million by offering 20 million ADSs at $16, within the range of $15 to $17. The company had originally planned to sell 16 million ADSs. Dada Nexus plans to list on the Nasdaq under the symbol DADA.

Calliditas Therapeutics, a Swedish biotech developing therapies for orphan kidney and liver diseases, raised $90 million in an upsized IPO by offering 4.6 million ADS equivalents at $19.50 per ADS. It originally planned to raise $75 million by offering 3.8 million ADS equivalents

ARYA Sciences Acquisition II, the second healthcare-focused blank check company formed by Perceptive Advisors, raised $130 million by offering 13 million units at $10. The company originally planned to offer 12.5 million units. Each unit consists of one share of common stock and

Shift4 Payments, which provides secure payment processing solutions, raised $345 million by offering 15 million shares at $23, above the range of $19 to $21. The Allentown, PA-based company plans to list on the NYSE under the symbol FOUR. Citi, Credit Suisse, Goldman Sachs, BofA

Applied Molecular Transport, a Phase 1 biotech developing novel oral therapies for inflammatory diseases, raised $154 million by offering 11 million shares at $14, the high end of the range of $12 to $14. The company originally filed to sell 10 million shares. Applied Molecular T